Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

A Primer on Imaging in Myositis

Rochelle Castillo, MD, MS, Andro Licaros, MD, & Jemima Albayda, MD  |  Issue: November 2022  |  

Jul;46(7):1174–1179.

  • Malartre S, Bachasson D, Mercy G, et al. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021 May;31(3):e12954.
  • Smith AC, Parrish TB, Abbott R, et al. Muscle-fat MRI: 1.5 Tesla and 3.0 Tesla versus histology. Muscle Nerve. 2014 Aug;50(2):170–176.
  • Malartre S, Bachasson D, Mercy G, et al. ibid.
  • Güttsches A-K, Rehmann R, Schreiner A, et al. Quantitative muscle-MRI correlates with histopathology in skeletal muscle biopsies. J Neuromuscul Dis. 2021;8(4):669–678.
  • Lassche S, Küsters B, Heerschap A, et al. Correlation between quantitative MRI and muscle histopathology in muscle biopsies from healthy controls and patients with IBM, FSHD and OPMD. J Neuromuscul Dis. 2020;7(4):495–504.
  • Albayda J, van Alfen N. Diagnostic value of muscle ultrasound for myopathies and myositis. Curr Rheumatol Rep. 2020 Sep 28;22(11):82.
  • Conticini E, Falsetti P, Al Khayyat SG, et al. A novel grey scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Rheumatology (Oxford). 2021 Dec 24;61(1):185–194.
  • Meng C, Adler R, Peterson M, Kagen L. Combined use of power Doppler and grayscale sonography: A new technique for the assessment of inflammatory myopathy. J Rheumatol. 2001 Jun;28(6):1271–1282.
  • Leeuwenberg KE, Alfen N van, Christopher-Stine L, et al. Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle Nerve. 2020 Jun;61(6):783–788.
  • Chaudhari AJ, Raynor WY, Gholamrezanezhad A, et al. Total-body PET imaging of musculoskeletal disorders. PET Clin. 2021 Jan;16(1):99–117.
  • Wahl RL, Herman JM, Ford E. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. Semin Radiat Oncol. 2011 Apr;21(2):88–100.
  • Noto Y-I, Kondo M, Tsuji Y, et al. Diagnostic value of muscle [11C]PIB-PET in inclusion body myositis. Front Neurol. 2020 Jan 17;10:1386.
  • Lilleker JB, Hodgson R, Roberts M, et al. [18F]Florbetapir positron emission tomography: Identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019 May;78(5):657–662.
  • Zhang Y, Li K, Pu C, Dang H, Liu J, Shi Q. A novel application of tau PET in the diagnosis of sporadic inclusion body myositis: A case report. Medicine (Baltimore). 2020 Jul 31;99(31):e21524.
  • Kundrick A, Kirby J, Ba D, et al. Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. Semin Arthritis Rheum. 2019 Aug;49(1):140–144.
  • Liang J, Cao H, Liu Y, et al. The lungs were on fire: A pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease. Arthritis Res Ther. 2021 Jul;23(1):198.

    • Related Articles

      New Tools for Myositis Diagnosis, Classification & Management

      CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

      Autoantibodies in Autoimmune Myopathy

      Autoantibodies in Autoimmune Myopathy

      In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…